🇺🇸 FDA
Pipeline program

Norovirus Bivalent Vaccine

LV03-105

Phase 2 mab completed

Quick answer

Norovirus Bivalent Vaccine for Prevention From Norovirus Infection is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Prevention From Norovirus Infection
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials